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Abstract
Background: The objective of this article is to describe the organisation of an international, clinical registry, the
Chronic Kidney Disease Observational Database (CKDOD), the processes of enrolling patients and entering data
and preliminary results to date.
Design: The Chronic Kidney Disease Observational Database (CKDOD) is designed to assess the association between
different factors with a known influence on chronic kidney disease (CKD) progression as well as treatment strategies
such as dietary modifications, blood pressure control and pharmacological interventions in Asian countries (India,
China, Malaysia and Thailand). The only inclusion criterion is the presence of CKD stage 2 or higher as defined by the
KDIGO guidelines. Demographic and clinical information are collected by a standardised electronic questionnaire,
available in English and Chinese. The data are transferred to the CKDOD database either by e-mail or via web access.
All data are checked for consistency and missing values.
Collection of data started in September 2011 and by April 2015, data on 1323 individual patients had been
submitted. The mean age at inclusion was 57 ± 14 years, 67 % were male and 36 % were diabetic. The baseline
estimated glomerular filtration rate was 26 ml/min/1.73 m2. Of all enrolled patients, 324 (24 %) received ketoanalogue
supplementation during at least one recorded visit.
Discussion: The CKDOD is a very large and comprehensive data repository, currently focused in subjects recruited
from Asia. The database is expected to provide important long-term information on CKD progression, nutritional and
metabolic derangements that accompany CKD progression and treatment strategies to ameliorate progression and
complications of CKD.
Trial Registration: Clinical Trial Registry – India: CTRI/2012/06/002743; 25th July 2012
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Background
Chronic kidney disease (CKD) is known to be progressive,
gradually leading to end-stage renal disease (ESRD) [1]. In-
cidence and prevalence of CKD are increasing with high
burden of morbidity and mortality accounting for 1.4 % of
all global deaths in 2010 [2]. Furthermore, CKD patients
are far more likely to die from cardiovascular disease before
they develop ESRD [3]. Therefore, the actual health and hu-
manistic burden of CKD is underestimated when only
death caused by kidney failure is considered. Consequently,
CKD, which usually leads to dialysis, has a major impact on
public health care and possesses a significant economic and
social strain on many countries. India, as well as many
developing countries, does not have reimbursement from
government for management of ESRD including mainten-
ance dialysis or transplantation. Of the approximately
100,000 Indian patients who develop ESRD each year, 90 %
never see a nephrologist. Of those patients who actually
start maintenance dialysis, about 60 % are lost to follow up
within three months because of the high costs [4].
Loss of kidney function in CKD can be delayed but
generally cannot be reversed. Therefore, slowing down
progression towards ESRD and amelioration of nutri-
tional and metabolic complications of CKD are the
mainstay of CKD management. Especially in countries
where renal replacement therapy is not affordable for
the majority of the population, a delayed progression to
ESRD could significantly increase life expectancy. Fac-
tors that influence development and progression of CKD
include hypertension, hyperglycaemia, dyslipidaemia,
obesity, age, smoking, history of cardiovascular disease
and exposure to nephrotoxic agents. Most of these fac-
tors also directly influence the nutritional and metabolic
status of the CKD patients. The relative contribution of
most of the factors towards the progression of CKD have
not yet been evaluated in long-term trials, especially in
developing countries where most CKD patients are not
offered renal replacement therapy [1].
The Chronic Kidney Disease Observational Database
(CKDOD) is designed to assess the association between
different factors with a known influence on CKD pro-
gression as well as treatment strategies such as dietary
modifications, keto acid supplementation, blood pres-
sure control and pharmacological interventions in Asian
countries. CKDOD aims to document practice patterns
and long-term outcomes of CKD patients with the over-
all goal of providing opportunities for potential treat-
ment strategies. The current manuscript describes the
rationale, design and preliminary results of CKDOD.
Methods
Organisation and objectives of the registry
CKDOD was initiated by an informal group of Indian
nephrologists in 2011 and initially included four centres
from India. By 2014, the registry included 12 centres
from India, Malaysia, China and Thailand.
The primary objectives of the registry are the evaluation
of the current practise patterns for management of CKD
patients in Asian countries as well as the analysis of asso-
ciations between different treatment strategies, including
but not limited to nutritional interventions (low protein
diet and ketoanalogue supplementation) and blood pres-
sure control and the rate of progression of CKD, incidence
of ESRD, transplantation and death. Secondary objectives
include assessing the incidence of cardiovascular events,
incidence and causes of comorbidities, clinically signifi-
cant laboratory abnormalities related to metabolic and
hormonal derangements as well as quality of life scores.
Collection of data
All data in the registry are collected following approval
by the corresponding ethics committees of the partici-
pating centres (See Additional file 1 for SPIRIT Check-
list) (Lancelot Independent Ethics Committee, Mumbai,
India; Ethics Committee Sir Ganga Ram Hospital, Delhi,
India; Shatabdi Hospital Ethics Committee, Nashik, India;
Clinical Research Ethics Committee of the MEDICA
Superspecialty Hospital, Kolkata, India; St. John’s Medical
College & Hospiutal Institutional Ethical Review Board,
Bangalore, India; Institutional Ethics Committee of the
Dr. Tam Manohar Lohia Hospital, New Delhi, India; Med-
ical Ethics Committee of the University Malaya Medical
Centre, Kuala Lumpur, Malaysia; Khon Kaen University
Ethics Committee for Human Research, Khon Kaen,
Thailand; Medical Ethics Committee of the Qilu Hospital
of Shandong University, Shandong, China).
The main inclusion criterion for the registry is the
presence of CKD stages 2 to 5 not on dialysis, defined
by an estimated glomerular filtration rate (eGFR) below
90 ml/min per 1.73 m2. Other inclusion criteria include
individuals aged at least 18 years, with a regular attend-
ance at a given clinical site, a life expectancy of at least
six months and written informed consent. The responsi-
bility of obtaining and storing written informed consent
lies with the participating centres. Patients are excluded
if they have or have had a kidney transplant, sustained
sitting systolic blood pressure (BP) > 160 mmHg and sit-
ting diastolic BP > 110 mmHg despite appropriate ther-
apy or an independent life-threatening disease such as
active cancer, HIV or end-stage liver or heart disease.
Each participating physician or his/her staff transfers
the data from source documents (medical records) to
the secured (username/password protected) CKDOD
website (online data collection tool) or the offline data
collection tool. The offline version is used for sites
where internet is inaccessible or connection is unstable.
Data input to the website updates the database in real
time. Data input to the offline data collection tool is
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transferred to the online database once internet connec-
tion becomes available.
Each centre is provided with a unique login ID (user
name) and password. The user can only see the patients
entered by his centre. The identity of the patient is not
visible in the web application.
Data analysis is done after patient de-identification
for the data coordinating site. Anonymity of the data
is assured by coding the included patients with an
identification number consisting of a four-digit field
automatically generated by the web application. Once
assigned to a patient, the patient number is not re-
placed or reused. The actual patient name is only
known to the participating centre and is not saved in
the database. Only the centres keep lists with the
names of the patients and the respective identifica-
tion number.
The data management team performs consistency
checks and issues electronic data clarification forms to
follow up on discrepant data. Data exceeding plausible
ranges or missing data are identified by the data acquisi-
tion programme during data entry. A quarterly manual
review is done to check consistency and completeness of
data. Study sites receive monthly reports on data quality
and completeness in order to verify, correct, or complete
irregular or missing data. If data modification is re-
quired, changes on the CKDOD website database are
only conducted after confirmation from the source doc-
uments by the responsible investigator or study nurse.
This study does not require any study specific treat-
ments or investigations. Patients are treated and man-
aged according to the physicians’ clinical judgment.
During the study period, data are recorded from assess-
ments and evaluations performed according to routine
practice and standard care at the centres and subse-
quently entered into a web-based data portal. The data
for this study are collected for each patient until death,
renal transplant, and withdrawal of consent or loss to
follow up due to any other reason. Data collected at en-
rollment includes baseline demographic data and pre-
sumed cause of CKD. The questionnaire is completed at
each visit, including the day of enrollment, includes data
on serum and urinary parameters, dialysis, comorbidi-
ties, medications, nutritional interventions and quality of
life (Additional file 2). Patients who have no visit record
for more than one year or have died, received a renal
transplant or were transferred to a different centre are
considered as lost to follow up. Figure 1 depicts the
documentation procedure.
During the follow up period, no diagnostic or monitor-
ing procedures additional to standard care and routine
practice are applied. Only data originating from assess-
ments and evaluations performed according to the cen-
tres’ routine practice are recorded for the purpose of
this study. Patient visit intervals are chosen at the physi-
cian’s discretion and according to their standard of care.
Analysis
A first preliminary and solely descriptive analysis has
been performed for this particular report. For all param-
eters shown in Table 2, the mean and standard deviation
has been calculated for the total population and for each
country separately.
After the end of the documentation period, correla-
tions between different factors influencing the progres-
sion of CKD as well as treatment strategies and the rate
of progression towards ESRD will be calculated. Primary
endpoints are progression of CKD defined by reaching
CKD stage 5 and decline of GFR during the study
period. Standard analyses will be carried out to describe
patients and clinical practices, overall and by subgroups
defined by dietary protein and energy intake, as well as
keto acid supplementation. Multivariate regression
models will be used to study the associations between
patient characteristics, clinical practices, or nutritional
interventions and the progression of CKD. We calcu-
lated the required sample size assuming 20 % of patients
receiving keto acid treatment and based on published
data [5]. Targeting a power of 0.9 the required sample
size is about 700 patients. For detection of differences of
GFR decline this number would also be sufficient
expecting data similar to previously published data [6].
Taking into account possible drop out and less defined
conditions as in the two RCTs we aim at including at
least 1,500 patients to the registry.
Results
The number of patients for whom data has been submit-
ted is shown in Fig. 2. Collection of data began in
September 2011 and by April 2015, data from 1323 indi-
viduals has been submitted. Table 1 shows the number
of subjects by country and the year when each country
included its first patient (updated April 2015). The mean
age of the subjects was 57 years (range 18–102 years; SD
14 years) and 67 % were male. Additional baseline data
is shown in Table 2.
The most often entered primary cause of CKD was
hypertension, followed by diabetes mellitus (33 % of the
patients had only hypertension, 24 % only diabetes, and
12 % both hypertension and diabetes, Fig. 3). At the first
recorded visit, the majority of patients had CKD stage 4
(35 %), followed by stage 3 (27 %), and stage 5 (26 %).
Of all enrolled patients, 237 (17,9 %) were vegetarians.
228 (17,2 %) consulted a dietician at least at one visit
and 194 (14,7 %) were using a nutrition diary. The aver-
age recommended caloric intake at the first visit was
29,0 kcal/kg body weight daily. The estimated actual cal-
oric intake was 28,8 kcal/kg. 375 (28 %) were prescribed
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a low or very low diet. Of these, 324 (24 %) received
ketoanalogue supplementation at least once. The usual
dose was six tablets per day. 249 (19 %) of the patients
were on a low or very low protein diet without ketoana-
logue supplementation (Table 2).
Discussion
In the present paper, we describe the design of Chronic
Kidney Disease Observational Database, an international
pragmatic cohort study aimed at providing informa-
tion on practice patterns of CKD management in
developing countries with limited access to renal
replacement therapies.
The worldwide increase in prevalence of CKD and the
enormous costs of treatment are already a major burden
in developed countries, but the impact of CKD on devel-
oping countries is far more challenging. The clinical,
epidemiologic, and socioeconomic effects of CKD are
expected to be greatest in low- or middle-income coun-
tries, which comprise about 85 % of the world’s popula-
tion. By the year 2030, an estimated 70 % of patients
with ESRD will be residents of these countries [7]. Due
to the absence of any registry, the actual incidence of
Fig. 1 Documentation procedure
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ESRD can only be estimated for India or other south-
ern Asian countries [8]. In addition to the treatment
of patients with ESRD the organisational and financial
resources needed for the prevention and detection of
CKD pose a major problem for low- or middle-
income countries.
Besides missing information on incidence and preva-
lence of CKD and ESRD, little is known about the actual
treatment of patients in India and other Asian countries.
A large Asian registry including patients treated at
numerous nephrology centres offers the opportunity to
assess current treatment practices and analyse the effects
of different treatment strategies on the progression of
CKD with the aim of improving treatment practice in
the long run.
With 1323 subjects enrolled (last updated April
2015), CKDOD is a large and comprehensive registry
for monitoring the progression of CKD in Asia. This
registry is to our knowledge the first of its kind to
combine information on CKD progression, treatment
and nutritional intervention in a long-term data col-
lection. A search at ClinicalTrials.gov revealed 566
observational studies with the term “chronic kidney
disease” and 46 studies when the term “diet” was
added. However, to our knowledge no other observa-
tional study focuses on the interactions between the
type of protein restriction (low protein diet), the sup-
plementation with ketoanalogues and the progression
of CKD, which might be a very important especially
in low resource settings for mangement of advanced
CKD. In Germany, a large chronic kidney disease
registry with more than 6000 included patients is ex-
pected to reveal interesting information about clinical
treatment variation and the impact of clinical treat-
ments on survival, quality of life and cost [9]. How-
ever, to our knowledge this registry does not consider
information on diet and nutritional supplementation.
The Chronic Renal Insufficiency Cohort (CRIC) study
started in the US [10] uses a detailed food question-
naire to evaluate possible effects of nutritional habits
but does not focus on protein restriction and ketoa-
nalogue supplementation. The Chronic Kidney Dis-
ease Japan Cohort (CKD-JAC) study focuses on
correlation of CKD and cardiovascular disease. [11]
The Korean KNOW-CKD study [12] does not seem
to focus on nutritional aspects. Finally, the French
Chronic Kidney Disease-Renal Epidemiology and In-
formation Network (CKD-REIN) has a strong focus
on pharmacoeconomic aspects but also not on nutri-
tion.[13] The Indian Clinical Database of Kidney
Diseases (CDKD) collects kidney-related physiological
data [14] but no information on diet of CKD patients
and is no longer maintained. The United States Renal
Data System (USRDS) may be the largest data collec-
tion on CKD, but provides mainly data on incidence
and prevalence and not on progression or nutritional
management.
Table 1 The number of patients included in the CKDOD
registry by country. Last updated in April 2015






Fig. 2 Cumulative increase of patients included into the CKDOD registry. By April 2015, a total of 1323 individuals were included in the registry
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Running CKDOD with a large Indian population
also provides us with the opportunity to study the
progression of CKD under ketoanalogue supplemen-
tation in patients with a habitually low protein in-
take. Patel et al. showed that even without protein
restriction, protein intake was 0.65 g/kg/day in
Indian CKD patients [15], which is very close to a
low protein diet. CKDOD will not only result in
valuable information about a treatment approach
which relies highly on patient compliance and co-
operation, but also provide the opportunity of com-
paring clinical courses and outcomes of different
ethnic groups with widely differing diets. The devel-
opment of a shared questionnaire, the adoption of
minimum requirements to ensure quality control and
the electronic transfer of data, either by e-mail or by
a secure web-enabled database, greatly contributes to
the success of the CKDOD data validation, dissemin-
ation and rapid growth.
In a recent publication, Aparicio et al. [16] showed that
a ketoanalogue-supplemented very low protein diet
(sVLPD) can postpone dialysis treatment. Furthermore,
Garneata and Mircescu reported that sVLPD can effect-
ively ameliorate metabolic disturbances of advanced CKD
and delay the initiation of dialysis without deleterious
effects on nutritional status. Piccoli et al. [17] found prom-
ising results in terms of mortality and CKD progression
for pre-dialysis patients with a supplemented low protein
diet. The CKDOD registry is expected to add valuable
long-term pragmatic data of a large patient population
and shed further light on the possibility to delay dialysis
with the right combination of diet and supplementation.
In summary, CKDOD is expected to reveal important
information regarding the practice patterns for the care
of CKD patients with a specific emphasis on nutritional
and metabolic aspects. These data could generate hy-
potheses for future research or clinical projects in the
management of CKD patients.
Table 2 Demographic data and baseline information
Total India Thailand Malaysia China
Number of patients enrolled, N 1323 1137 56 80 50
Males, % 881 (67 %) 759 (67 %) 36 (64 %) 53 (66 %) 33 (66 %)
Age, mean (SD) 57 (±14) 56 (±14) 67 (±12) 68 (±10) 50 (±15)
BMI, mean (SD) 25.2 (±4.8) 25.2 (±4.8) 24.1 (±4.8) 26.8 (±5.7) 24.6 (±3.4)
First blood pressure in mmHg, mean (SD) 135/81 (±15/10) 134/83 (±15/9) 133/68 (±17/11) 139/74 (±15/13) 132/82 (±13/11)
First creatinine in mg/dL, mean (SD) 3.2 (±1.9) 3.4 (±2.0) 2.6 (±1.2) 2.4 (±0.6) 2.1 (±1.3)
First eGFR in ml/min/1.73 m2 (EPI), mean (SD) 26.0 (±16.4 25.0 (±16.2) 26.8 (±12.2) 26.8 (±8.4) 44.8 (±23.0)
Patients on low or very low protein diet with
ketoanalogue supplementation at any visit, %
324 (24 %) 284 (25 %) 2 (4 %) 20 (25 %) 18 (36 %)
Patients on low or very low protein diet without
ketoanalogue supplementation at any visit, %
249 (19 %) 178 (16 %) 4 (7 %) 37 (46 %) 30 (60 %)
Fig. 3 Primary cause of CKD. More than one cause could be selected
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Additional files
Additional file 1: SPIRIT Checklist for the CKDOD. Items 11, 17, 22, 30
and 33 were not applicable due to the observational nature of the study
and lack of any biospecimen collection. (DOCX 22 kb)
Additional file 2: Chronic Kidney Disease Observational Database
subject data collection forms. The information was collected by the
research staff or the study investigators and subsequently transferred to
the secured (username/password protected) CKDOD website (online data
collection tool) or the offline data collection tool. The offline version is
used for sites where internet is inaccessible or connection is unsecure.
(PDF 141 kb)
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